The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
Status:
Completed
Trial end date:
2017-04-28
Target enrollment:
Participant gender:
Summary
This is a 2 parts phase I, open label trial of olaparib monotherapy and olaparib in
combination with paclitaxel in patients with solid tumours. Part A will assess the single and
multiple dose pharmacokinetics of olaparib monotherapy and multiple dose pharmacokinetics of
olaparib in combination with paclitaxel. Part B will assess the safety of multiple doses of
olaparib in Cohort 1 and of olaparib when co-administered with paclitaxel in Cohort 2